NEW YORK, April 29 (GenomeWeb News) - Genaissance Pharmaceuticals announced today that it has signed an amendment to its license agreement with the University of Utah and Yale University relating to cardiac ion channel genes associated with sudden cardiac death syndromes.
The amendment will simplify royalty payments for various genetic tests, including those for cardiac ion channel mutations, the company said. In addition, it will extend Genaissance's licensing rights to the patent estate.
Genaissance originally acquired the license agreement in May 2003 with the acquisition of most of the assets of DNA Sciences, whose IP portfolio included patents developed at Utah and Yale for diagnosing Long QT, Brugada and related syndromes associated with the cardiac ion channel genes.
The company said it expects to launch its test for cardiac ion channel mutations in May.